Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China · Delayed Price · Currency is CNY 6.15
-0.21 (-3.30%)
Nov 13, 2026, 3:04 PM CST
SHE:002550 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,502 | 1,563 | 1,524 | 1,809 | 2,302 | 1,874 |
Other Revenue | 8.37 | 8.37 | 2.39 | 5.17 | 1.13 | 1.02 |
| 1,510 | 1,571 | 1,526 | 1,814 | 2,304 | 1,875 | |
Revenue Growth | -1.52% | 2.95% | -15.88% | -21.24% | 22.86% | 12.43% |
Cost of Revenue | 691.6 | 665.35 | 696.31 | 1,045 | 1,419 | 1,045 |
Gross Profit | 818.76 | 905.92 | 829.94 | 768.81 | 884.31 | 829.44 |
Selling, General & Admin | 437.63 | 462.75 | 423.58 | 521.42 | 541.03 | 587.29 |
Research & Development | 127.17 | 110.66 | 104.45 | 97.08 | 88.31 | 71.18 |
Other Operating Expenses | 19.92 | 11.96 | 13.75 | 7.13 | 17.1 | 18.35 |
Operating Expenses | 700.15 | 585.25 | 547.81 | 606.62 | 661.74 | 677.06 |
Operating Income | 118.61 | 320.67 | 282.12 | 162.19 | 222.56 | 152.38 |
Interest Expense | -0.36 | -0.46 | -1.39 | -5.93 | -5.23 | -1.66 |
Interest & Investment Income | 18.16 | 21.57 | 21.49 | 19.3 | 5.64 | 1.6 |
Currency Exchange Gain (Loss) | -14.12 | -14.12 | 3.73 | 1.26 | 74.02 | -5.4 |
Other Non Operating Income (Expenses) | 98.32 | 114.75 | 84.85 | -1.83 | -0.02 | 52.55 |
EBT Excluding Unusual Items | 220.6 | 442.41 | 390.8 | 175 | 296.97 | 199.48 |
Gain (Loss) on Sale of Investments | 14.26 | 6.55 | 2.36 | 0.77 | -4.59 | 0.64 |
Gain (Loss) on Sale of Assets | 0.06 | 0.01 | - | 25.35 | 57.59 | - |
Asset Writedown | -0.1 | -0.1 | -0.04 | -7.77 | -0.24 | -0.46 |
Other Unusual Items | 6.44 | 1.31 | 2.72 | 10.18 | 10.6 | 9.72 |
Pretax Income | 241.27 | 450.18 | 395.84 | 203.52 | 360.33 | 209.38 |
Income Tax Expense | 39.6 | 76.93 | 62.66 | 24.85 | 40.42 | 23.04 |
Earnings From Continuing Operations | 201.67 | 373.25 | 333.18 | 178.67 | 319.91 | 186.34 |
Minority Interest in Earnings | 29.06 | 25.54 | 22.85 | 3.19 | 3.5 | -5.26 |
Net Income | 230.73 | 398.8 | 356.03 | 181.86 | 323.41 | 181.08 |
Net Income to Common | 230.73 | 398.8 | 356.03 | 181.86 | 323.41 | 181.08 |
Net Income Growth | -46.30% | 12.01% | 95.77% | -43.77% | 78.60% | - |
Shares Outstanding (Basic) | 1,253 | 1,246 | 1,272 | 1,299 | 1,294 | 1,207 |
Shares Outstanding (Diluted) | 1,253 | 1,246 | 1,272 | 1,299 | 1,294 | 1,207 |
Shares Change | -1.29% | -1.99% | -2.11% | 0.41% | 7.16% | 0.58% |
EPS (Basic) | 0.18 | 0.32 | 0.28 | 0.14 | 0.25 | 0.15 |
EPS (Diluted) | 0.18 | 0.32 | 0.28 | 0.14 | 0.25 | 0.15 |
EPS Growth | -45.60% | 14.29% | 100.00% | -44.00% | 66.67% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 162.31 | 219.76 | 424.07 | 433 | -142.46 | 13.19 |
Free Cash Flow Per Share | 0.13 | 0.18 | 0.33 | 0.33 | -0.11 | 0.01 |
Dividend Per Share | 0.150 | 0.150 | 0.120 | 0.120 | 0.120 | 0.120 |
Dividend Growth | 25.00% | 25.00% | 0% | 0% | 0% | 0% |
Gross Margin | 54.21% | 57.66% | 54.38% | 42.38% | 38.39% | 44.24% |
Operating Margin | 7.85% | 20.41% | 18.48% | 8.94% | 9.66% | 8.13% |
Profit Margin | 15.28% | 25.38% | 23.33% | 10.02% | 14.04% | 9.66% |
Free Cash Flow Margin | 10.75% | 13.99% | 27.79% | 23.87% | -6.18% | 0.70% |
EBITDA | 182.86 | 385.45 | 347.61 | 231.41 | 287.33 | 221.82 |
EBITDA Margin | 12.11% | 24.53% | 22.78% | 12.75% | 12.47% | 11.83% |
D&A For EBITDA | 64.25 | 64.78 | 65.49 | 69.22 | 64.76 | 69.43 |
EBIT | 118.61 | 320.67 | 282.12 | 162.19 | 222.56 | 152.38 |
EBIT Margin | 7.85% | 20.41% | 18.48% | 8.94% | 9.66% | 8.13% |
Effective Tax Rate | 16.41% | 17.09% | 15.83% | 12.21% | 11.22% | 11.00% |
Revenue as Reported | 1,510 | 1,571 | 1,526 | 1,814 | 2,304 | 1,875 |